What the FDA labels say about taking them together
Buprenorphine and bupropion/naltrexone
Bupropion/naltrexone's FDA label of November 10, 2025 names buprenorphine in its contraindications section; the buprenorphine labels PlainMeds reads (4) do not name bupropion/naltrexone. The bupropion/naltrexone label: “… Chronic opioid or opiate agonist (e.g., methadone) or partial agonists (e.g., buprenorphine) use, or acute opiate withdrawal Patients undergoing an abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and …”
Check it at the source: the buprenorphine FDA label on DailyMed (effective June 5, 2026); the bupropion/naltrexone FDA label on DailyMed (effective November 10, 2025, Nalpropion Pharmaceuticals LLC).
What does the buprenorphine label say about bupropion/naltrexone?
Buprenorphine's label (effective June 5, 2026) and its 3 other brand-application labels do not name bupropion/naltrexone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Buprenorphine HCl), SpecGx LLC, effective June 5, 2026 (SPL set b60d514d-a88a-4fa2-a5b0-30ac29e04973), via openFDA; the full label on DailyMed
What does the bupropion/naltrexone label say about buprenorphine?
Bupropion/naltrexone label, contraindicationsCONTRAINDICATIONS CONTRAVE is contraindicated in Uncontrolled hypertension [see Warnings and Precautions (5.5) ] Seizure disorder or a history of seizures [see Warnings and Precautions (5.3) ] Use of other bupropion-containing products (including, but not limited to, WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, APLENZIN and ZYBAN) Bulimia or anorexia nervosa, which increase the risk for seizure [see Warnings and Precautions (5.3) ] Chronic opioid or opiate agonist (e.g., methadone) or partial agonists (e.g., buprenorphine) use, or acute opiate withdrawal [see Warnings and Precautions (5.4) and Drug Interactions (7.2) ] Patients undergoing an abrupt discontinuation of alcohol, benzodiazepines …
Bupropion/naltrexone label, warnings and precautionsAn opioid-free interval of a minimum of 7 to 10 days is recommended for patients previously dependent on short- acting opioids, and those patients transitioning from buprenorphine or methadone may need as long as two weeks.
Source: FDA drug label (Contrave Extended-Release), NDA200063 (Azurity), as published by Nalpropion Pharmaceuticals LLC, effective November 10, 2025 (SPL set 485ff360-32c8-11df-928b-0002a5d5c51b), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Buprenorphine | Bupropion/naltrexone | |
|---|---|---|
| Labeled for | Opioid use disorder, Pain | Weight management |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.277 per tablet 2 mg tablet sl | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once